Pomalidomide: when expectations are understated

Future Oncol. 2017 Feb;13(5s):1-2. doi: 10.2217/fon-2016-0559.
No abstract available

Keywords: drug resistance; immunomodulatory drugs; multiple myeloma; pomalidomide.

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Drug Resistance, Neoplasm
  • Humans
  • Immunologic Factors / therapeutic use*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Retreatment
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Immunologic Factors
  • Thalidomide
  • pomalidomide